Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
Journal: Journal of neurology
Published: July 07, 2023
Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab: New York State Multiple Sclerosis Consortium (NYSMSC) study.
Journal: Journal of the neurological sciences
Published: June 22, 2023
Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC).
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: December 22, 2022
Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.
Journal: Multiple sclerosis and related disorders
Published: April 21, 2021
COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: May 11, 2020
Anti-John Cunningham virus antibody index levels in multiple sclerosis patients treated with rituximab, fingolimod, and dimethyl fumarate.
Journal: Surgical neurology international
Published: January 08, 2019
Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC).
Journal: BMC neurology
Published: January 07, 2016
Few patients with neurodegenerative disorders require spinal surgery.
Journal: Surgical neurology international
Published: October 13, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026